Multiple Therapeutic Applications of RBM-007, an Anti-FGF2 Aptamer

Multiple Therapeutic Applications of RBM-007, an Anti-FGF2 Aptamer

Vascular endothelial growth factor (VEGF) plays a pivotal role in angiogenesis, but is not the only player with an angiogenic function. Fibroblast growth factor-2 (FGF2), which was discovered before VEGF, is also an angiogenic growth factor. It has been shown that FGF2 plays positive pathophysiologi...

Full description

Bibliographic Details
Main Author: Yoshikazu Nakamura
Format: Article
Language:English
Published: MDPI AG 2021-06-01
Series:Cells
Subjects:
fibroblast growth factor 2
RNA aptamer
age-related macular degeneration
achondroplasia
lung cancer
cancer pain
Online Access:https://www.mdpi.com/2073-4409/10/7/1617
id doaj-abc5f068246b40cab9ecd24691e00f65
record_format Article
spelling doaj-abc5f068246b40cab9ecd24691e00f652021-07-23T13:34:39ZengMDPI AGCells2073-44092021-06-01101617161710.3390/cells10071617Multiple Therapeutic Applications of RBM-007, an Anti-FGF2 AptamerYoshikazu Nakamura0Division of RNA Medical Science, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, JapanVascular endothelial growth factor (VEGF) plays a pivotal role in angiogenesis, but is not the only player with an angiogenic function. Fibroblast growth factor-2 (FGF2), which was discovered before VEGF, is also an angiogenic growth factor. It has been shown that FGF2 plays positive pathophysiological roles in tissue remodeling, bone health, and regeneration, such as the repair of neuronal damage, skin wound healing, joint protection, and the control of hypertension. Targeting FGF2 as a therapeutic tool in disease treatment through clinically useful inhibitors has not been developed until recently. An isolated inhibitory RNA aptamer against FGF2, named RBM-007, has followed an extensive preclinical study, with two clinical trials in phase 2 and phase 1, respectively, underway to assess the therapeutic impact in age-related macular degeneration (wet AMD) and achondroplasia (ACH), respectively. Moreover, showing broad therapeutic potential, preclinical evidence supports the use of RBM-007 in the treatment of lung cancer and cancer pain.https://www.mdpi.com/2073-4409/10/7/1617fibroblast growth factor 2RNA aptamerage-related macular degenerationachondroplasialung cancercancer pain
collection DOAJ
language English
format Article
sources DOAJ
author Yoshikazu Nakamura
spellingShingle Yoshikazu Nakamura
Multiple Therapeutic Applications of RBM-007, an Anti-FGF2 Aptamer
Cells
fibroblast growth factor 2
RNA aptamer
age-related macular degeneration
achondroplasia
lung cancer
cancer pain
author_facet Yoshikazu Nakamura
author_sort Yoshikazu Nakamura
title Multiple Therapeutic Applications of RBM-007, an Anti-FGF2 Aptamer
title_short Multiple Therapeutic Applications of RBM-007, an Anti-FGF2 Aptamer
title_full Multiple Therapeutic Applications of RBM-007, an Anti-FGF2 Aptamer
title_fullStr Multiple Therapeutic Applications of RBM-007, an Anti-FGF2 Aptamer
title_full_unstemmed Multiple Therapeutic Applications of RBM-007, an Anti-FGF2 Aptamer
title_sort multiple therapeutic applications of rbm-007, an anti-fgf2 aptamer
publisher MDPI AG
series Cells
issn 2073-4409
publishDate 2021-06-01
description Vascular endothelial growth factor (VEGF) plays a pivotal role in angiogenesis, but is not the only player with an angiogenic function. Fibroblast growth factor-2 (FGF2), which was discovered before VEGF, is also an angiogenic growth factor. It has been shown that FGF2 plays positive pathophysiological roles in tissue remodeling, bone health, and regeneration, such as the repair of neuronal damage, skin wound healing, joint protection, and the control of hypertension. Targeting FGF2 as a therapeutic tool in disease treatment through clinically useful inhibitors has not been developed until recently. An isolated inhibitory RNA aptamer against FGF2, named RBM-007, has followed an extensive preclinical study, with two clinical trials in phase 2 and phase 1, respectively, underway to assess the therapeutic impact in age-related macular degeneration (wet AMD) and achondroplasia (ACH), respectively. Moreover, showing broad therapeutic potential, preclinical evidence supports the use of RBM-007 in the treatment of lung cancer and cancer pain.
topic fibroblast growth factor 2
RNA aptamer
age-related macular degeneration
achondroplasia
lung cancer
cancer pain
url https://www.mdpi.com/2073-4409/10/7/1617
work_keys_str_mv AT yoshikazunakamura multipletherapeuticapplicationsofrbm007anantifgf2aptamer
_version_ 1721289024496205824

Similar Items